An inter-laboratory in vitro assessment of cigarettes and next generation nicotine delivery products.


Journal

Toxicology letters
ISSN: 1879-3169
Titre abrégé: Toxicol Lett
Pays: Netherlands
ID NLM: 7709027

Informations de publication

Date de publication:
15 Oct 2019
Historique:
received: 11 03 2019
revised: 16 07 2019
accepted: 06 08 2019
pubmed: 11 8 2019
medline: 24 9 2019
entrez: 11 8 2019
Statut: ppublish

Résumé

In vitro testing can facilitate the rapid assessment of next generation nicotine delivery products (NGPs) with comparisons to combustible tobacco products. In vitro assays for cytotoxicity and oxidative stress were employed at BAT (UK) and JT (Japan) to test total particulate matter (TPM) of a scientific reference cigarette and aerosol collected mass (ACM) of a commercially available E-cigarette and two tobacco heating products (THP). 3R4F TPMs were generated using the Health Canada intense (HCI) regimen, a modified regime (mHCI) for the THP ACMs and the CORESTA recommended method no. 81 for the E-cigarette ACM. Human lung cells were exposed to the test product TPM/ACMs at concentrations between 0-200 μg/ml followed by the employment of commercially available assays for endpoint analysis that included reactive oxygen species (ROS) generation, the glutathione ratio (GSH:GSSG), activation of the antioxidant response elements (ARE) and cellular viability. TPM/ACM nicotine concentrations were quantified using a UPLC-PDA technique. At both laboratories the 3R4F TPM induced significant and dose-dependent responses in all in vitro assays, whereas no significant responses could be measured for the NGP ACMs. In conclusion, both laboratories obtained comparable results across all endpoints therefore demonstrating the utility of the in vitro techniques combined with standardised test products to support the assessment of NGPs.

Identifiants

pubmed: 31400404
pii: S0378-4274(19)30219-X
doi: 10.1016/j.toxlet.2019.08.004
pii:
doi:

Substances chimiques

Aerosols 0
Particulate Matter 0
Nicotine 6M3C89ZY6R

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

14-22

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Shigeaki Ito (S)

Japan Tobacco Inc., R&D Group, Yokohama, Japan.

Mark Taylor (M)

British American Tobacco, R&D, Southampton, UK. Electronic address: markr_taylor@BAT.com.

Sakura Mori (S)

Japan Tobacco Inc., R&D Group, Yokohama, Japan.

David Thorne (D)

British American Tobacco, R&D, Southampton, UK.

Tomoki Nishino (T)

Japan Tobacco Inc., R&D Group, Yokohama, Japan.

Damien Breheny (D)

British American Tobacco, R&D, Southampton, UK.

Marianna Gaça (M)

British American Tobacco, R&D, Southampton, UK.

Kei Yoshino (K)

Japan Tobacco Inc., R&D Group, Yokohama, Japan.

Christopher Proctor (C)

British American Tobacco, R&D, Southampton, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH